Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Viread Tenofovir disoproxil fumarate HIV infection N/A Complete
Viread Tenofovir disoproxil fumarate Hepatitis B (chronic) List with clinical criteria and/or conditions Complete
Visanne Dienogest Pain, pelvic pain associated with endometriosis List with clinical criteria and/or conditions Complete
Vitrakvi Larotrectinib NTRKplus solid tumours Do not reimburse Complete
Vitrakvi larotrectinib Solid tumours with NTRK gene fusion Reimburse with clinical criteria and/or conditions Complete
Vizimpro Dacomitinib Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Vocabria and Cabenuva cabotegravir sodium cabotegravir-rilpivirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Volibris Ambrisentan Pulmonary arterial hypertension (WHO class II and III) List with clinical criteria and/or conditions Complete
Vonvendi von Willebrand Factor [recombinant] von Willebrand disease, adults, treatment and perioperative management Reimburse with clinical criteria and/or conditions Complete
Vosevi sofosbuvir velpatasvir voxilaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Votrient Pazopanib hydrochloride Metastatic Renal Cell Carcinoma Reimburse Complete
Votrient Pazopanib hydrochloride Metastatic Renal Cell Carcinoma Reimburse Complete
Votrient Pazopanib Hydrochloride Soft Tissue Sarcoma Do not reimburse Complete
Voydeya danicopan Paroxysmal nocturnal hemoglobinuria (PNH) Reimburse with clinical criteria and/or conditions Active
VPRIV Velaglucerase alfa Gaucher Disease List with clinical criteria and/or conditions Complete
Vraylar cariprazine Bipolar Disorder Do not reimburse Complete
Vraylar cariprazine Schizophrenia Do not reimburse Complete
Vraylar cariprazine Schizophrenia Reimburse with clinical criteria and/or conditions Active
Vyalev foslevodopa foscarbidopa Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Vyepti eptinezumab Migraine Reimburse with clinical criteria and/or conditions Complete
Vyndaqel tafamidis transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyndaqel tafamidis Transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyvanse Lisdexamfetamine dimesylate Attention deficit hyperactivity disorder Do not list Complete
Vyvgart efgartigimod alfa Generalized myasthenia gravis (gMG) Reimburse with clinical criteria and/or conditions Complete
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete